Welcome to our dedicated page for Allstate SEC filings (Ticker: ALL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Allstate Corporation filings document the insurer's operating results, Regulation FD updates, governance matters and registered capital structure. Recent Form 8-K reports include quarterly and annual financial results, investor supplements, estimated catastrophe losses and policies in force for Allstate Protection.
Allstate's proxy materials describe board matters, executive compensation and shareholder voting items. Its filing cover pages identify common stock, fixed-to-floating subordinated debentures due 2053, and depositary shares representing Series H, Series I and Series J noncumulative preferred stock registered on public exchanges.
The Allstate Corporation’s Chairman, President & CEO Thomas J. Wilson reported multiple open-market sales of company common stock on January 12, 2026. Across several trades coded as sales, he sold a total of 16,807 shares at weighted average prices ranging from $205.6779 to $209.9939, with actual sale prices spanning from $205.30 to $210.42.
The filing notes that these transactions were carried out under a Rule 10b5-1 trading plan adopted on June 27, 2025, indicating they were pre-arranged. Following the reported sales, Wilson directly beneficially owns 94,408.303 shares of Allstate common stock. He also reports indirect holdings, including 31,900 shares held by a 2024-C GRAT and 69,822 shares held by a 2025-A GRAT, along with additional trust and plan positions.
Allstate Corporation executive Suren Gupta, President, Enterprise Solutions, reported an employee stock option exercise and related stock sale. On January 7, 2026, he exercised an employee stock option for 19,593 shares of Allstate common stock at an exercise price of $62.32 per share and acquired the underlying shares. On the same date, he reported selling 19,593 shares of Allstate common stock at a reported price of $210 per share.
After these transactions, Gupta directly owned 100,646 shares of Allstate common stock. He also had indirect holdings of 1,335 shares through a 401(k) plan and 7 shares through VVG Holdings LLC.
Form 144 shows that Suren K. Gupta plans to sell 19,593 shares of common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $4,114,530.00. The issuer has 261,681,708 shares outstanding, and the sale is expected around 01/07/2026.
The shares come from stock options granted on 02/11/2016 and acquired for cash on 01/07/2026. The filing also lists several prior sales of common stock during November 2025, including 21,871 shares sold on 11/21/2025 for $4,706,912.59, indicating ongoing share disposals by the same seller.
The Allstate Corporation’s Chairman, President and CEO Thomas J. Wilson reported multiple open-market sales of Allstate common stock on January 2, 2026. The Form 4 shows four sale transactions of common stock at weighted average prices of $204.0964, $204.8644, $206.1694, and $206.9005, with corresponding post-transaction direct beneficial ownership levels of 120,826.303, 113,590.303, 112,450.303, and 111,215.303 shares.
The filing states these sales were executed under a Rule 10b5-1 trading plan adopted on June 27, 2025. It also notes that Wilson’s holdings include additional indirect ownership through several GRATs, a 401(k) plan, and a GRAT remainder trust, reflecting substantial ongoing equity exposure to Allstate.
The Allstate Corporation director reports routine stock compensation. On 01/01/2026, director Jacques P. Perold acquired 204 shares of Allstate common stock at $208.15 per share. The shares were received under The Allstate Corporation 2017 Equity Compensation Plan for Non-Employee Directors as stock in lieu of cash compensation. After this transaction, he beneficially owned 204 Allstate shares directly and 35 shares indirectly through a trust.
Allstate Corporation director Margaret M. Keane reported a routine equity compensation transaction. On 01/01/2026, she acquired 162 shares of Allstate common stock at $208.15 per share through an election to receive stock instead of cash fees under Allstate’s 2017 Equity Compensation Plan for Non-Employee Directors. After this and prior activity, she beneficially owns 16,514.718 shares of Allstate common stock. This balance includes 76.041 shares accumulated between July 3, 2025 and January 2, 2026 through a dividend reinvestment program.
The Allstate Corporation director reports routine equity compensation activity. On 01/01/2026, the reporting person acquired 198 shares of Allstate common stock at $208.15 per share, electing to receive stock instead of cash fees under The Allstate Corporation 2017 Equity Compensation Plan for Non-Employee Directors. After this transaction, the director directly owned 5,653.379 Allstate common shares, which also include 48.254 shares accumulated through dividend reinvestment between July 3, 2025 and January 2, 2026.
The filing also shows 7,703.604 common share units held under The Allstate Corporation Amended and Restated Deferred Compensation Plan for Non-Employee Directors, representing deferred director fees and dividend equivalents. For the period from October 2, 2025 through January 2, 2026, the director received 37.612 additional common share units from dividends credited under this deferred compensation arrangement.
A holder of common stock in issuer ALL, identified as the Thomas J. Wilson Revocable Trust, has filed to sell 100,842 shares of common stock on the NYSE through Goldman Sachs & Co. LLC. The planned sale has an aggregate market value of $20,553,616.44, compared with 261,681,708 shares of common stock outstanding.
The shares to be sold were originally acquired from the issuer on 02/21/2012 as compensation through performance awards. Over the past three months, the same trust has completed multiple sales of 16,807 shares of common stock on several dates, each generating multimillion-dollar gross proceeds, indicating an ongoing selling program under Rule 144.
Allstate Corporation Chairman, President & CEO Thomas J. Wilson reported several internal transfers of Allstate common stock involving his personal trusts and direct ownership. On December 19, 2025, 61,308 shares previously held by the Thomas J. Wilson 2023-B GRAT Trust were distributed to his direct ownership, and 50,134 shares from the same 2023-B GRAT were transferred to the Thomas J. Wilson 2020 GRAT Remainder Trust at a reported price of $0 per share.
The filing also notes a distribution of 33,421 shares from the Thomas J. Wilson 2024-C GRAT Trust to direct ownership on the same date. After receiving these shares, he contributed a total of 94,729 shares to the Thomas J. Wilson 2025-E GRAT Trust. Following these moves, he continues to hold Allstate stock directly and indirectly through multiple GRATs and a 401(k) plan.
The Allstate Corporation furnished a Regulation FD report to provide access to its November 2025 monthly release on estimated catastrophe losses and policies in force.
The company states that this release is posted on allstateinvestors.com and is attached as Exhibit 99, a press release dated December 18, 2025 that is furnished, not filed.